Hardcore performance! ADC CRDMO's leading player, Wuxi Apptec (02268), continues to "soar" in the first half of the year: new signed projects hit a record high, project reserves increase in quality and quantity, and production capacity layout radiates globally.

According to the Securities Times APP, as a leading company in the field of biological conjugate drug CRDMO, WuXi Biologics (02268) released its performance announcement for the first half of 2025 on the evening of August 18, once again stunning the market with outstanding performance leading the industry. In the first half of 2025, the company's revenue increased by 62.2%, far exceeding the annual growth rate guidance. From the first half of 2022 to the first half of 2025, the company's annual compound growth rate (CAGR) of revenue reached a high of 98%. After years of rapid growth, the company's market share has continued to rise significantly since 2022, reaching approximately 22% in the first half of 2025. These astonishing numbers not only demonstrate the sustained strong development momentum of the biological conjugate drug track, but also fully confirm the unshakable benchmark position of WuXi Biologics in the industry, leading the unstoppable momentum.